The benefits of the use of anti-Cgrp monoclonal antibodies on migraine patients are at the center of the ‘Take a journey into migraine’ event, organized these days in Bologna (29 February and 1 March).
The latest data from real-life studies on anti-Cgrp monoclonal antibodies, i.e. studies based on clinical practice data relating to patients taking these therapies all over the world, show how anti-Cgrp are effective and safe drugs in the preventive treatment of migraine.
In the studies presented, the antibody used prophylactically was administered as a subcutaneous injection, monthly or sometimes quarterly, to patients who suffered from 4 or more migraine days per month, resulting in a significant reduction in the number of monthly days with migraine.
At an Italian level, however, not all patients can access this treatment under the reimbursement regime by the healthcare system, but only patients who have had at least three previous treatment failures and have at least 8 days of headache per month.
breaking latest news © Copyright ANSA